Hualan Vaccine
Hualan Vaccine
Hualan Vaccine Henan province
Hualan Bio Vaccine, founded in 2005 and headquartered in Xinxiang, Henan province, is a modern vaccine manufacturer, mainly developing and producing human bacterial vaccines, viral vaccines, genetic engineering vaccines and other high-tech products. Its main competitors include Changsheng and GDK
- All
- News
- Analysis
- Research
In depth
Briefing Jan 13, 2022 10:05 AM
· Healthcare
West Lake Omei won hundreds of millions of yuan of pre-A round of financing to help clinical diagnosis and AI new drug research and development based on proteome big data
Briefing Jan 12, 2022 09:28 AM
· Healthcare
Zhenge biology obtained US $100 million in round C financing, led by Goldman Sachs and Sofina
Apr 22, 2021 03:11 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Jan 10, 2022 09:00 PM
· Healthcare
Bristol Myers Squibb entered the development of IPSC derived allogeneic cell therapy with more than US $3 billion
Briefing Jan 10, 2022 11:16 AM
· Healthcare
Lanjing microorganism completed a total of RMB 1.5 billion of Series B financing and accelerated the implementation of the "T-type" development strategy
Briefing Jan 10, 2022 09:37 AM
· Healthcare
Synthetic biology enterprise Lanjing microorganism completed a total of 1.5 billion yuan of Series B financing
Briefing Jan 06, 2022 05:02 PM
· Healthcare
Yourui pharmaceutical acquired Zhongjian pharmaceutical to create a special pharmaceutical company driven by two wheels of innovative pipeline R & D and commercialization of mature products
Briefing Jan 06, 2022 03:39 PM
· Healthcare
Xinmai medical announced strategic cooperation with rainbow medical, a famous medical device incubator in Israel
Briefing Jan 06, 2022 11:27 AM
· Healthcare
Hengrui medicine has been introduced for more than US $100 million! New antifungal drugs applied for listing in China
Briefing Jan 06, 2022 09:28 AM
· Healthcare
Jiangsu new element medicine completed a round C financing of more than 300 million yuan, and the gout innovative medicine has a good curative effect
In depth
Healthcare
Dada group's revenue rose nearly 30% in the third quarter, and JD's "hour purchase" cont
Looking forward to the fourth quarter of 2021, dada Group expects its total revenue to be between 2 billion yuan and 2.1 billion yuan. On the premise that the last kilometer of dada express delivery service is consistent with the comparable basis, the total revenue in the fourth quarter of 2021 will achieve a year-on-year increase of 88% to 97%.
Nov 24, 2021 11:42 AM
Briefing Jan 06, 2022 09:26 AM
· Healthcare
Jiayue pharmaceutical completed nearly 200 million yuan of B + round financing and promoted the mid and late stage clinical projects of innovative drug pipeline
Briefing Dec 31, 2021 06:27 PM
· Healthcare
The IPO of Lianying medical technology innovation board has been accepted by Shanghai Stock Exchange
Briefing Dec 31, 2021 05:55 PM
· Healthcare
Hengrui pharmaceutical CDK4 / 6 inhibitor approved! Treatment of advanced breast cancer
See more
Related Companies
EqualOcean Analysis
- Wuxi Apptec Embraces a More Health-Conscious China
- Four Growing Stocks to Watch in the Dynamic Chinese Market
- Genetron Health's Self-Developed Mutation Capsule Differentiates It from Others
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.